1887

Abstract

Purpose. To determine the timing of the emergence of macrolide-resistant mutations after macrolide treatment in individuals with Mycoplasma pneumoniae infections.

Methodology. Between October 2011 and December 2013, serial pharyngeal swab specimens were collected before and after macrolide treatment from 21 otherwise healthy children infected with M. pneumoniae without macrolide-resistant mutations. The copy numbers of a M. pneumoniae gene and the proportion of clones showing macrolide-resistance mutations were determined for each specimen.

Results. After macrolide treatment (10–15 mg kg day clarithromycin for 5–10 days or 10 mg kg day azithromycin for 3 days), fever resolved in 19 (90 %) of 21 children within 1 to 2 days, and the M. pneumoniae gene copy number decreased in all but one specimen in the second set of specimens relative to the number in the corresponding initial specimens. None of the second specimens, which were collected 2–4 days after initiation of macrolide treatment, showed mutations in the 23S rRNA gene. However, the proportion of mutant clones with A2063G and A2064G mutations in the specimens collected 7–24 days after initiation of treatment increased to 100 %. We identified a family in which three members had M. pneumoniae infections. The analysis of transmission in this household indicated that the M. pneumoniae harbouring a macrolide-resistant mutation that developed in the index patient after macrolide treatment was not transmitted to the family members.

Conclusion. A macrolide-resistant population might develop in individual patients up to 24 days after initiation of macrolide treatment. However, the decrease in M. pneumoniae load after macrolide administration effectively reduces interpersonal transmission.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000582
2017-10-06
2019-12-09
Loading full text...

Full text loading...

/deliver/fulltext/jmm/66/11/1531.html?itemId=/content/journal/jmm/10.1099/jmm.0.000582&mimeType=html&fmt=ahah

References

  1. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004;17:697–728 [CrossRef][PubMed]
    [Google Scholar]
  2. Yamazaki T, Kenri T. Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae. Front Microbiol 2016;7:693 [CrossRef][PubMed]
    [Google Scholar]
  3. Okazaki N, Narita M, Yamada S, Izumikawa K, Umetsu M et al. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol 2001;45:617–620 [CrossRef][PubMed]
    [Google Scholar]
  4. Pereyre S, Goret J, Bébéar C. Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol 2016;7:974 [CrossRef][PubMed]
    [Google Scholar]
  5. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother 2008;52:348–350 [CrossRef][PubMed]
    [Google Scholar]
  6. Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother 2010;16:78–86 [CrossRef][PubMed]
    [Google Scholar]
  7. Ubukata K, Morozumi M, Iwata S. Large epidemic of Mycoplasmal pneumonia caused by Mycoplasma pneumoniae strains highly resistant to macrolides among children in 2011. IASR 2011;32:337–339
    [Google Scholar]
  8. Kawai Y, Miyashita N, Kubo M, Akaike H, Kato A et al. Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients. Antimicrob Agents Chemother 2013;57:4046–4049 [CrossRef][PubMed]
    [Google Scholar]
  9. Ishiguro N, Koseki N, Kaiho M, Kikuta H, Togashi T et al. Regional differences in prevalence of macrolide resistance among pediatric Mycoplasma pneumoniae infections in Hokkaido, Japan. Jpn J Infect Dis 2016;69:186–190 [CrossRef][PubMed]
    [Google Scholar]
  10. Suzuki Y, Seto J, Itagaki T, Aoki T, Abiko C et al. Gene mutations associated with macrolide-resistance and p1 gene typing of Mycoplasma pneumoniae Isolated in Yamagata, Japan, between 2004 and 2013. Kansenshogaku Zasshi 2015;89:16–22 [CrossRef][PubMed]
    [Google Scholar]
  11. Pereyre S, Guyot C, Renaudin H, Charron A, Bébéar C et al. In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae. Antimicrob Agents Chemother 2004;48:460–465 [CrossRef][PubMed]
    [Google Scholar]
  12. Lucier TS, Heitzman K, Liu SK, Hu PC. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. Antimicrob Agents Chemother 1995;39:2770–2773 [CrossRef][PubMed]
    [Google Scholar]
  13. Ohya H, Suzuki I, Narita M, Okazaki N. In vitro development of macrolide-resistant Mycoplasma pneumoniae and transition mutation in 23Sr RNA of resistance strains. Jpn J Mycoplasmol 2008;35:47–52
    [Google Scholar]
  14. Chironna M, Sallustio A, Esposito S, Perulli M, Chinellato I et al. Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. J Antimicrob Chemother 2011;66:734–737 [CrossRef][PubMed]
    [Google Scholar]
  15. Averbuch D, Hidalgo-Grass C, Moses AE, Engelhard D, Nir-Paz R. Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010. Emerg Infect Dis 2011;17:1079–1082 [CrossRef][PubMed]
    [Google Scholar]
  16. Cardinale F, Chironna M, Dumke R, Binetti A, Daleno C et al. Macrolide-resistant Mycoplasma pneumoniae in paediatric pneumonia. Eur Respir J 2011;37:1522–1524 [CrossRef][PubMed]
    [Google Scholar]
  17. Hantz S, Garnier F, Peuchant O, Menetrey C, Charron A et al. Multilocus variable-number tandem-repeat analysis-confirmed emergence of a macrolide resistance-associated mutation in Mycoplasma pneumoniae during macrolide therapy for interstitial pneumonia in an immunocompromised child. J Clin Microbiol 2012;50:3402–3405 [CrossRef][PubMed]
    [Google Scholar]
  18. Itagaki T, Suzuki Y, Seto J, Abiko C, Mizuta K et al. Two cases of macrolide resistance in Mycoplasma pneumoniae acquired during the treatment period. J Antimicrob Chemother 2013;68:724–725 [CrossRef][PubMed]
    [Google Scholar]
  19. Dumke R, Stolz S, Jacobs E, Juretzek T. Molecular characterization of macrolide resistance of a Mycoplasma pneumoniae strain that developed during therapy of a patient with pneumonia. Int J Infect Dis 2014;29:197–199 [CrossRef][PubMed]
    [Google Scholar]
  20. Suzuki Y, Itagaki T, Seto J, Kaneko A, Abiko C et al. Community outbreak of macrolide-resistant Mycoplasma pneumoniae in Yamagata, Japan in 2009. Pediatr Infect Dis J 2013;32:237–240 [CrossRef][PubMed]
    [Google Scholar]
  21. Leven M, Ursi D, van Bever H, Quint W, Niesters HG et al. Detection of Mycoplasma pneumoniae by two polymerase chain reactions and role of M. pneumoniae in acute respiratory tract infections in pediatric patients. J Infect Dis 1996;173:1445–1452 [CrossRef][PubMed]
    [Google Scholar]
  22. Matsuoka M, Narita M, Okazaki N, Ohya H, Yamazaki T et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother 2004;48:4624–4630 [CrossRef][PubMed]
    [Google Scholar]
  23. Sasaki T, Kenri T, Okazaki N, Iseki M, Yamashita R et al. Epidemiological study of Mycoplasma pneumoniae infections in Japan based on PCR-restriction fragment length polymorphism of the P1 cytadhesin gene. J Clin Microbiol 1996;34:447–449[PubMed]
    [Google Scholar]
  24. Dégrange S, Cazanave C, Charron A, Renaudin H, Bébéar C et al. Development of multiple-locus variable-number tandem-repeat analysis for molecular typing of Mycoplasma pneumoniae. J Clin Microbiol 2009;47:914–923 [CrossRef][PubMed]
    [Google Scholar]
  25. Chalker VJ, Pereyre S, Dumke R, Winchell J, Khosla P et al. International Mycoplasma pneumoniae typing study: interpretation of M. pneumoniae multilocus variable-number tandem-repeat analysis. New Microbes New Infect 2015;7:37–40 [CrossRef][PubMed]
    [Google Scholar]
  26. Thurman KA, Warner AK, Cowart KC, Benitez AJ, Winchell JM. Detection of Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella spp. in clinical specimens using a single-tube multiplex real-time PCR assay. Diagn Microbiol Infect Dis 2011;70:1–9 [CrossRef][PubMed]
    [Google Scholar]
  27. Suzuki Y, Seto J, Shimotai Y, Ikeda T, Yahagi K et al. Development of an endpoint genotyping assay to detect the Mycoplasma pneumoniae 23S rRNA gene and distinguish the existence of macrolide resistance-associated mutations at position 2063. J Microbiol Methods 2016;131:130–134 [CrossRef][PubMed]
    [Google Scholar]
  28. Nilsson AC, Björkman P, Persson K. Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection. BMC Microbiol 2008;8:93 [CrossRef][PubMed]
    [Google Scholar]
  29. Foy HM. Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin Infect Dis 1993;17:S37–S46 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000582
Loading
/content/journal/jmm/10.1099/jmm.0.000582
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error